Transplant Drugs

Organ transplant
Biotech

Triple phase 3 disaster sends AlloVir shares plunging 64%

AlloVir’s ambitions, like its share price, have shrunk significantly as the biotech abandons three late-stage trials of its lead asset
James Waldron Dec 22, 2023 9:00am
Organ transplant

Immunosuppressant antibody curbs chronic transplant rejection

Apr 24, 2023 11:05am
A graphic displaying a cross-section of the kidneys

AlloVir's cell therapy tackles virus in kidney transplant trial

Feb 15, 2023 9:45am
Novartis Switzerland

Novartis stops liver transplant program due to weak phase 2 data

Oct 25, 2022 6:00am